United Therapeutics Corp
NASDAQ:UTHR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
274.7
517.13
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
UTHR
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 468.935 USD,
United Therapeutics Corp
is
hidden
.
Valuation History
United Therapeutics Corp
UTHR looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether UTHR usually does or if today's premium is unusual.
Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for United Therapeutics Corp.
Fundamental Analysis
UTHR Profitability Score
Profitability Due Diligence
Score
UTHR Solvency Score
Solvency Due Diligence
Score
Select up to 3 indicators:
Select up to 3 indicators:
Significant reliance on its pulmonary arterial hypertension (PAH) franchise exposes United Therapeutics to competition from newer therapies and potential generic entrants, which could erode its leading market share and pricing power.
United Therapeutics has maintained a strong foothold in PAH treatments with established therapies such as Tyvaso, Orenitram, and Remodulin, supported by steady demand and favorable reimbursement, driving stable cash flow.
Revenue & Expenses Breakdown
United Therapeutics Corp
Balance Sheet Decomposition
United Therapeutics Corp
United Therapeutics Corp
Free Cash Flow Analysis
United Therapeutics Corp
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
United Therapeutics Corp
Wall St
Price Targets
UTHR Price Targets Summary
United Therapeutics Corp
According to Wall Street analysts, the average 1-year price target for
UTHR
is 539.746 USD
with a low forecast of 427.23 USD and a high forecast of 677.25 USD.
Dividends
Current shareholder yield for
UTHR is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
UTHR
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 468.935 USD,
United Therapeutics Corp
is
hidden
.